Kaly Patents- its a disclaimerincase any one hasn't read the Nov 29th MD&A, its a typical disclaimer that is commonly posted. has zero doom and gloom regarding the companys state: This MD&A contains certain forward-looking statements and certain forward-looking information as defined under applicable Canadian securities laws that may not be based on historical fact, including, without limitation, statements containing the words believe, may, plan, will, estimate, continue, anticipate, intend, expect and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of Kalyteras experience and perception of historical trends, current conditions and expected future developments, as well as the factors Kalytera believes are appropriate. Forward-looking statements in this MD&A include but are not limited to statements relating to: the initiation, timing, cost, progress and success of Kalyteras research and development programs, pre-clinical studies and clinical trials; Kalyteras ability to advance product candidates into, and successfully complete, clinical trials; Kalyteras ability to recruit sufficient numbers of patients for Kalyteras future clinical trials; Kalyteras ability to achieve profitability; Kalyteras ability to obtain funding for Kalyteras operations, including funding for research and commercial activities; Kalyteras ability to establish and maintain relationships with collaborators with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts; whether Kalyteras third party collaborators will maintain their intellectual property rights in the technology Kalytera licenses; the implementation of Kalyteras business model and strategic plans; Kalyteras ability to develop and commercialize product candidates; Kalyteras anticipated regulatory submissions and commercial activities; Kalyteras estimates of the size and characteristics of the potential markets for its product candidates; 28929713.2 - 2 - Kalyteras commercialization, marketing and manufacturing capabilities and strategy; Kalyteras ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; Kalyteras expectations regarding federal, provincial and foreign regulatory requirements; whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in the U.S., Canada, the European Union and other jurisdictions; the therapeutic benefits, effectiveness and safety of Kalyteras product candidates; the rate and degree of market acceptance and clinical utility of Kalyteras future products, if any; the timing of, and Kalyteras ability and its collaborators ability, if any, to obtain and maintain regulatory approvals for its product candidates; Kalyteras expectations regarding market risk, including interest rate changes and foreign currency fluctuations; Kalyteras ability to engage and retain the employees required to grow its business; the compensation that is expected to be paid to employees of the Company; Kalyteras future financial performance and projected expenditures; developments relating to Kalyteras competitors and its industry, including the success of competing therapies that are or may become available; and estimates of Kalyteras expenses, future revenue, capital requirements and its needs for additional financing. Such statements reflect Kalyteras current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Kalytera, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause Kalyteras actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this MD&A, the Company has made various material assumptions, including, but not limited to: (i) enrollment in, completion of and obtaining positive results from clinical trials; (ii) obtaining regulatory approvals; (iii) general business and economic conditions; (iv) the Companys ability to develop and commercialize, or otherwise monetize, its product candidates and in-license and develop new products; (v) the assumption that Kalyteras current good relationships with its collaborators, licensors and other third parties will be maintained; (vi) the availability of financing on reasonable terms; (vii) the Companys ability to attract and retain skilled staff; (viii) the products and technology offered by the Companys competitors; and (ix) the Companys ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors, including the risks outlined under the heading Financial Instruments and Risks and under the heading Risk Factors in the Companys 2018 Annual Information Form (2018 AIF) filed on SEDAR (www.sedar.com) on April 30, 2019. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materializes, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this MD&A, and Kalytera does not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.